


## Fanotaprim

## Chemical Properties

|                   |   |
|-------------------|---|
| CAS No. :         | 2120282-75-7  |
| Formula:          | C19H22N8O   |
| Molecular Weight: | 378.43  |
| Storage:          | Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br>Actual storage temperature shall be subject to the COA. |



## Biological Description

|                            |  |
|----------------------------|--|
| Description                | Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor, suppressing the growth of <i>T. gondii</i> strains with a TgDHFR IC <sub>50</sub> of 1.57 ± 0.11 nM, a hDHFR IC <sub>50</sub> of 308 ± 71 nM, and a hDHFR to TgDHFR selectivity ratio of 196.  |
| Targets(IC <sub>50</sub> ) | Antifolate, DHFR   |
| In vitro                   | Fanotaprim exhibits parasitocidal and antiproliferative effects with EC <sub>50</sub> s of 13 and 7300 nM against the type I RH strain of <i>T. gondii</i> and MCF-7 cells, respectively[1]. It also inhibits the growth of <i>T. gondii</i> strains in vitro with EC <sub>50</sub> s ranging from 7.6 to 29.8 nM (GT1, ME49, CTG, RUB, and VAND)[1].  |
| In vivo                    | Fanotaprim (1-10 mg/kg; p.o.; daily; beginning on day 1 through day 7) is highly effective in controlling acute infection by highly virulent strains of <i>T. gondii</i> in the murine model[1]. In mice, Fanotaprim (1 mg/kg; i.v.) shows CL, V <sub>d</sub> , and t <sub>1/2</sub> values of 10.6 mL/min/kg, 1.14 L/kg, and 3.9 hours, respectively[1]. When administered orally at 0.83 mg/kg, Fanotaprim exhibits F, C <sub>max</sub> , T <sub>max</sub> , and AUC <sub>0-last</sub> values of 47.3%, 178 ng/mL, 0.05 hours, and 750 ng h/mL, respectively[1]. |

## Solubility Information

|                     |   |
|---------------------|---|
| Solubility          | DMSO: 25 mg/mL (66.06 mM), Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)  |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.28 mM), Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | 1mg       | 5mg        | 10mg      |
|-------|-----------|------------|-----------|
| 1 mM  | 2.6425 mL | 13.2125 mL | 26.425 mL |
| 5 mM  | 0.5285 mL | 2.6425 mL  | 5.285 mL  |
| 10 mM | 0.2642 mL | 1.3212 mL  | 2.6425 mL |
| 50 mM | 0.0528 mL | 0.2642 mL  | 0.5285 mL |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019;62(3):1562-1576.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481